FGF3 — gene · CancerIndex

Curated evidence

Clinical evidence (3)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–3 of 3 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
FGF3 Amplification3
Dovitinib	Malignant Breast Neoplasm	Predictive	B	Supports Sensitivity Response	2	accepted	EID1606 81 patients were enrolled in a clinical trial with the FGFR inhibitor dovitinib. Four of these patients had FGF3 amplifications (qPCR) and showed tumor reductions of 100%, 30.8%, 23.0%, and 7.5%, resp… (full text at CIViC) PMID 23658459 · André et al., 2013 · Open in CIViC	civic
Sorafenib	Hepatocellular Carcinoma	Predictive	C	Supports Sensitivity Response	3	submitted	EID1966 FGF3/FGF4 amplification was observed in around 2% of HCCs. Although the sample size was relatively small, FGF3/FGF4 amplification, a poorly differentiated histological type, and multiple lung metastas… (full text at CIViC) PMID 22890726 · Arao et al., 2013 · Open in CIViC

Cohorts

Alteration frequency by cohort (37)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved37 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Colorectal Cancer (MSK, JCO Precis Oncol 2022) crc_dd_2022	Colorectal Adenocarcinoma	Ssm	4	47

Literature

Linked publications (1)

25 per page, newest first.

pubmedPublishedShowing 1–1 of 1 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
· Clin Cancer Res · 2013 · PMID 23658459 · validated civic_curation pubmed